RE: Q&A’s29 Sep 2020 17:21
And just like i said the Q&A would be released, plus a video out shortly, swiftly followed by the Japanese tie up...… Preclinical time line -
Repeated dose toxicity studies in one rodent and one non-rodent model
Should equal or exceed the duration of Phase I/II studies: (minimum 2 weeks, maximum 12 months; generally 1-3 months for biotech-derived products )
To support Phase III:
1 month
3 months
6 months
Japanese pharma agreement May...should be completed between June-November.... Soooooo this is going to be an exceptional Q4 in Valirx history. The next phase will be partnered for 201, to what extent? Suzy just said in the Q&A that the phase 2 study will now include other cancers. The 4mg dose had a higher count in human blood than the 100mg in rats. So why try higher? 201 has an excellent safety and tolerability so that's amazing data now for 301 and bc201. Amazing results after all? 30% success rate for marketed cancer drugs, 54.5% for 201. This is going to go ballistic. Well done Suzy and all involved.